MSC apoptosis after infusion has emerged as an important alternative to the older assumption that therapeutic mesenchymal stromal/stem cells must remain viable for prolonged periods. After systemic administration, many MSCs are transiently retained in the pulmonary microcirculation and may undergo apoptosis or other forms of cell death. Recipient immune cells can then recognize and process the dying cells. Experimental work suggests that the biological response to apoptotic MSCs may contribute to immunomodulatory effects. This does not mean that apoptosis is universally required or beneficial; the extent, timing, route dependence, product dependence, and clinical relevance of this mechanism remain active areas of investigation.
Figure 1 placeholder — MSC apoptosis after infusion
Efferocytosis
Efferocytosis is the regulated recognition and engulfment of apoptotic cells by phagocytes, particularly macrophages and monocytes. Unlike uncontrolled necrosis, efficient efferocytosis commonly promotes resolution-oriented signaling and limits release of intracellular inflammatory material. Apoptotic MSCs can expose 'eat-me' signals such as phosphatidylserine and can be engulfed by recipient phagocytes. The downstream response may include changes in cytokine production, metabolism, antigen presentation, and inflammatory tone. Demonstrating uptake of labeled MSC material, however, is not sufficient to establish efferocytosis unless apoptosis, phagocyte identity, and the fate of the engulfed material are adequately demonstrated.
Figure 2 placeholder — Efferocytosis
Macrophage reprogramming
Macrophage reprogramming describes a change in macrophage functional state after interaction with apoptotic cells or other biological signals. Following efferocytosis, macrophages can alter transcription, metabolism, cytokine secretion, antigen presentation, and communication with other immune cells. Experimental studies of MSC therapy suggest that phagocytosis of apoptotic or dying MSCs can contribute to host-mediated immunomodulation. The traditional M1/M2 framework is too coarse to define these responses reliably; functional assays and multidimensional phenotyping are preferable. A change in macrophage markers should not be equated automatically with a clinically beneficial immune response.
Figure 3 placeholder — Macrophage reprogramming
Implications for short cell persistence
Implications for short cell persistence are substantial. If administered MSCs can trigger biological effects through apoptosis, efferocytosis, and subsequent host-cell reprogramming, prolonged donor-cell survival is not necessarily required for activity. This helps reconcile observations of limited MSC persistence with biological effects in some experimental and clinical settings. It also changes how potency, biodistribution, dose, timing, and product viability may need to be interpreted. Short persistence is therefore neither proof of treatment failure nor proof of efficacy. The relevant question is whether the administered product initiates a reproducible, mechanistically relevant host response that translates into meaningful clinical benefit.
Figure 4 placeholder — Implications for short cell persistence
Clinical takeaway
An MSC does not necessarily need to engraft permanently to influence the recipient. In some settings, dying MSCs may be engulfed by host phagocytes and trigger downstream immune responses.
Apoptosis versus necrosis
Apoptosis is a regulated form of cell death that generally preserves membrane integrity during early stages, whereas necrotic injury can release intracellular contents and promote inflammation. Actual in-vivo cell death can involve overlapping pathways.
Recognition of apoptotic cells
Phosphatidylserine exposure and other molecular signals help phagocytes recognize dying cells. Bridging molecules and phagocytic receptors then coordinate uptake and downstream signaling.
Host-mediated mechanism
The active biological event may reside partly in the recipient rather than solely in the administered MSC. Monocytes and macrophages can become intermediaries that translate the presence of dying cells into systemic or local immune effects.
Viability and potency
High pre-infusion viability remains an important product-quality attribute, but post-administration apoptosis can still participate in mechanism. Manufacturing viability specifications and biological mechanism should not be treated as the same question.
Dose and route
The number of administered cells, route of delivery, vascular trapping, tissue environment, recipient inflammation, and clearance capacity may all influence how much apoptotic-cell processing occurs.
Safety implications
Cell death and clearance are normally regulated processes, but excessive cell burden, impaired clearance, complement activation, coagulation interactions, or release of intracellular material could alter safety.
Clinical interpretation
Evidence that MSCs disappear rapidly after infusion does not establish that they were biologically inactive. Conversely, a plausible apoptotic-cell mechanism does not prove clinical effectiveness.
Knowledge gaps
The frequency of MSC apoptosis in humans, the dominant phagocyte populations, organ-specific processing, dose-response relationships, biomarkers, and contribution to clinical outcomes remain incompletely defined.
Bottom-line evidence statement
Apoptotic-cell mechanisms provide a plausible explanation for biological activity despite short MSC persistence, but strong evidence requires direct demonstration of cell death, efferocytosis, host-cell reprogramming, and clinically relevant downstream effects.
Additional controlled terminology
Apoptosis is a regulated form of programmed cell death distinct from uncontrolled necrosis. A phagocyte such as a macrophage or monocyte can recognize phosphatidylserine as an eat-me signal, engulf an apoptotic body through phagocytosis, and complete clearance. Engulfment can promote resolution signaling rather than a sustained inflammatory response. This host-mediated mechanism may follow pulmonary trapping and helps separate cell persistence, biodistribution, donor-cell survival, and recipient response. Post-infusion viability is mechanistically distinct from a release-test measure of potency. Complement activation and coagulation interaction can influence safety. A cell-death biomarker may support mechanism, while immune reprogramming requires direct functional evidence.